Leqembi & Kisunla Brain Injury Lawsuits 2026: ARIA Risks, the 274 Volunteers Never Warned & Who Can File

Patients who suffered brain swelling or bleeding after taking Leqembi or Kisunla — and families of those who died — may have failure-to-warn claims against the drugmakers. Both Alzheimer’s drugs carry FDA boxed warnings for ARIA, and a New York Times investigation found hundreds of trial volunteers were never told they faced heightened brain-injury risk.

Key Facts

  • Leqembi’s FDA label reports ARIA in 21% of treated patients (191 of 898) versus 9% on placebo — brain swelling (ARIA-E) in 13%, brain bleeding (ARIA-H) in 17%.
  • Symptomatic ARIA struck 3% of Leqembi patients (29 of 898); serious symptoms hit 0.7%; brain hemorrhage larger than 1 cm occurred in 0.7% versus 0.1% on placebo — and the label notes fatal events have been observed.
  • The New York Times (November 2024) found that of nearly 2,000 trial volunteers, 274 with high-risk genetic profiles were never told their test results — and more than 100 volunteers suffered brain bleeding or swelling.
  • One 79-year-old volunteer died after three doses; her autopsy found her brain “riddled with 51 microhemorrhages,” the Times reported.
  • Europe’s medicines regulator refused to authorize Kisunla, ruling that its modest benefits did not outweigh the brain-injury risks.

What ARIA Actually Is — and Why It Can Kill

ARIA stands for amyloid-related imaging abnormalities — a plain-language definition: swelling in the brain (called ARIA-E) or bleeding in the brain (called ARIA-H), visible on an MRI scan. These drugs work by clearing sticky amyloid protein from the brain, and that same process can weaken blood-vessel walls. ARIA usually appears early in treatment and is often silent — but it can escalate into seizures, large brain hemorrhages, and death.

Risk is not spread evenly. People who carry two copies of the ApoE ε4 gene — roughly 15% of Alzheimer’s patients — suffered ARIA at a rate of 45% on Leqembi, per the FDA label. Patients on blood thinners face elevated danger too. That uneven risk sharpens the warning question: the people most likely to be harmed were identifiable in advance.

The 274 Volunteers Who Were Never Told

Volunteers signed consent forms saying they would be genetically tested for that risk — and that they would not be told the results. In the end, 274 high-risk volunteers entered the trial without ever learning how dangerous it was for them personally. More than 100 suffered brain bleeding or swelling; some died. For the families now pursuing claims, this is not a debate about fine print — it is about consent that was never truly informed, because the most important fact was deliberately withheld.

What the FDA Labels Say Today

Both drugs now carry boxed warnings — the FDA’s strongest alert — for ARIA. Leqembi’s prescribing information requires ApoE ε4 testing before treatment begins, urges caution for patients on anticoagulants or with vessel-wall amyloid, and mandates MRI monitoring, especially in the early months. Kisunla carries the same class-wide ARIA warning, and its European rejection stands as a stark official judgment: one major regulator concluded the drug’s benefits simply did not justify the brain-injury risk.

Leqembi won full FDA approval in July 2023 after its Clarity AD trial showed it slowed cognitive decline by 27% over 18 months — a real but modest benefit. Kisunla followed with FDA approval in July 2024. The lawsuits do not dispute that the drugs help some patients. They argue the companies failed to tell the right people, clearly enough, what the drugs could do to them — a pattern familiar from other pharmaceutical failure-to-warn battles, including the long-running Zantac litigation over an alleged cancer risk.

Who the Lawsuits Say Was Harmed

The claims fall into two groups. The first: clinical-trial volunteers who were not warned of their personal genetic risk — their cases center on informed consent, and the concealed test results are powerful evidence. The second: prescribed patients who developed ARIA after the drugs reached the market — their cases center on whether the warnings given to doctors and patients were adequate, and whether monitoring guidance came fast enough.

Families of patients who died from brain hemorrhage are pursuing wrongful-death claims; the FDA label itself acknowledges fatal intracerebral hemorrhages in Leqembi patients. Injury firms including Moll Law Group and Phillips Law have publicly announced investigations into Leqembi and Kisunla brain-injury claims — the same kind of failure-to-warn theory behind the Abilify compulsive-gambling claims, where patients said they were never adequately warned of a devastating side effect. As of late 2026, no federal multidistrict litigation (MDL) or class action has been consolidated — cases are being filed individually, which means each claim stands or falls on its own evidence.

What a Winning Claim Must Prove

A failure-to-warn case has three pillars. First, that the manufacturer knew — or should have known — about the risk; the companies’ own trial data and the genetic testing program make this hard to dispute. Second, that the warning was inadequate for the people actually at risk; the 274 undisclosed test results speak directly to this. Third, causation: medical records tying the patient’s brain swelling or bleeding to the drug. For prescribed patients, MRI scans showing ARIA after infusions began, against a clean baseline, form the backbone. Compensation varies widely by case, and most settlements are confidential; no lawyer can honestly promise a number before reviewing your records. Recent drug settlements, such as the $44 million Chantix settlement that reached final approval in 2026, show how long-running pharmaceutical cases can eventually resolve once the evidence picture is complete.

Deadlines: The Clock That Matters Most

Every state sets its own statute of limitations — the legal deadline to file — and most give only one to three years from the injury, or from when you reasonably discovered its cause. Trial-volunteer claims can involve different accrual rules than ordinary patient claims, because the concealed genetic information may delay when the clock starts. Do not try to calculate this yourself.

The practical point is blunt: waiting destroys claims. Medical records get harder to obtain, memories fade, and deadlines pass silently. If a loved one suffered brain bleeding or swelling during Leqembi or Kisunla treatment — or during one of the clinical trials — act now: preserve every medical record (infusion dates, MRI images, radiology reports), write a dated timeline of symptoms in the doctors’ own words, and sign nothing from any company without legal advice. Then speak with an attorney experienced in pharmaceutical mass-tort cases — most work on contingency, meaning no upfront fee; the lawyer is paid a percentage of any recovery, and nothing if the case loses. For plain-language explainers of complex health and money topics, the Problem Solved channel on YouTube breaks down difficult subjects into clear, practical guides.

Who Benefits From This — and Who Does Not

Clinical-trial volunteers who were never warned. If you took part in a trial and were not told of your personal genetic risk — the group at the center of the concealed-results findings — your case turns on informed consent, and the undisclosed test results are powerful evidence: preserve every trial record, infusion date, and MRI image.

Prescribed patients who developed ARIA. If you received Leqembi or Kisunla after approval and developed brain swelling or bleeding, your case turns on whether the warnings to doctors and patients were adequate and whether monitoring guidance came fast enough: MRI scans showing ARIA after infusions began, against a clean baseline, form the backbone of the claim.

Families of patients who died. If a loved one died from brain hemorrhage during treatment, wrongful-death claims are available to families, and the FDA label itself acknowledges fatal intracerebral hemorrhages: preserve the autopsy report and all imaging, since these records are often decisive.

Who does not benefit. If you took either drug without suffering ARIA or another covered injury, there is no injury to claim. If you are waiting for a class action or an MDL to join, note that as of late 2026 none has been consolidated — cases proceed individually, each on its own evidence. And no one should rely on a promised number: compensation varies widely by case, most settlements are confidential, and no lawyer can honestly promise a figure before reviewing your records. A related drug case is explained in our guide to Depo-Provera lawsuits.

Frequently Asked Questions

Can I still file a Leqembi lawsuit if I took the drug in 2024?

Possibly. It depends on your state’s filing deadline, whether you suffered ARIA or another covered injury, and when you discovered the connection. Trial-volunteer claims follow different timing rules because the genetic risk information was concealed — get an evaluation promptly.

Do I need to carry the ApoE ε4 gene to have a claim?

No. The gene raises the risk, but failure-to-warn and product-liability claims exist for any patient who suffered ARIA after what the lawsuits allege was inadequate warning — the 45% ARIA rate in homozygotes is evidence about risk, not a membership requirement.

Is there a Leqembi or Kisunla class action I can join?

As of late 2026, no federal MDL or class action has been announced for these drugs; cases are proceeding individually. That can actually help strong cases, because individual filings are evaluated on their own medical evidence rather than averaged into a group.

What if my loved one died after taking Leqembi or Kisunla?

Families may pursue wrongful-death claims, particularly where medical records show brain hemorrhage following treatment — the FDA label itself documents fatal intracerebral hemorrhages. Preserve the autopsy report and all imaging; these records are often decisive.

Who benefits from this guide, and how do I start?

The guide benefits trial volunteers who were never warned of their genetic risk, prescribed patients who developed ARIA after infusions, and families of patients who died from brain hemorrhage. Start here: preserve every medical record — infusion dates, MRI images, radiology reports — write a dated timeline of symptoms in the doctors' own words, and sign nothing from any company without legal advice; then speak with an attorney experienced in pharmaceutical mass-tort cases, most of whom work on contingency.

Who does not benefit — or who is not eligible?

Patients who took Leqembi or Kisunla without ARIA or another covered injury have no injury to claim. Anyone waiting for a class action or MDL will wait in vain for now: as of late 2026 no federal MDL or class action has been announced, and cases are filed individually. And anyone seeking a guaranteed payout figure should be cautious — compensation varies widely, settlements are usually confidential, and no honest figure exists before a records review.

This article is general information only — not legal or medical advice. Drug risks and legal deadlines are individual matters; consult a qualified attorney in your state and speak with your doctor before making any treatment decisions.

Watch on YouTube

Problem Solved on YouTube